RxDoctor Payments Data

Leilani Lim

Family · Orlando, FLNPI 1316468226

Payments from drug & device makers

$19,345in general payments, 2019–2025

Across 893 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$4K
  • AbbVie$3K
  • SK Life Science, Inc.$1K
  • Pfizer$952
  • Eisai Inc.$839
  • Jazz Pharmaceuticals Inc.$761
  • plus $9K from 42 others

What the payments were for

  • Speaking & faculty fees$680%
  • Food & beverage$19,259100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,345 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$18,335
Medicare patients
64
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)44$246,187
FinteplaFenfluramine Hcl13$235,378
Gamunex-CImmune Globul G/Gly/Iga Avg 4630$220,737
XcopriCenobamate119$182,307
FycompaPerampanel85$107,749
BriviactBrivaracetam52$79,667
Nurtec OdtRimegepant Sulfate41$65,972
NayzilamMidazolam37$65,747
AptiomEslicarbazepine Acetate26$37,471
Aimovig AutoinjectorErenumab-Aooe36$30,200
UbrelvyUbrogepant23$27,555
RytaryCarbidopa/Levodopa41$21,275
BotoxOnabotulinumtoxina17$21,135
Lamotrigine ErLamotrigine17$21,057
ValtocoDiazepam12$20,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Briviact, Nayzilam, Neupro$3,845$391,365113 claims
SK Life Science, Inc.Xcopri$1,424$182,307119 claims
Eisai Inc.Fycompa$839$107,74985 claims
PfizerNurtec Odt, Dilantin$952$66,54653 claims
AbbVieUbrelvy, Botox$2,719$48,69040 claims
Sunovion Pharmaceuticals Inc.Aptiom$213$37,47126 claims
Amneal Pharmaceuticals LLCRytary$140$21,27541 claims
Neurelis, Inc.Valtoco$603$20,20412 claims
Upsher-smith Laboratories LLCTopiramate$163$60762 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →